$ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Chen Schor
CEO
152
Employees
$7.63
Current Price
$66.19M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $468,081.99 | 72,939 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 4 | $674,847.06 | 104,658 | ||
| 3 months | Buys | 1 | 3 | $1,603,934.13 | 223,596 | 2.38:1 |
| Sells | 1 | 4 | $674,847.06 | 104,658 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | RA CAPITAL MANAGEMENT, L.P. 10% Owner | Purchase | 74,577 | $7.04 | $525,022.08 | View Details |
| Feb 19, 2026 | RA CAPITAL MANAGEMENT, L.P. 10% Owner | Purchase | 74,268 | $7.21 | $535,472.28 | View Details |
| Feb 20, 2026 | RA CAPITAL MANAGEMENT, L.P. 10% Owner | Purchase | 74,751 | $7.27 | $543,439.77 | View Details |
| Apr 8, 2026 | ORBIMED ADVISORS LLC 10% Owner | Sale | 32,523 | $6.29 | $204,569.67 | View Details |
| Apr 8, 2026 | ORBIMED ADVISORS LLC 10% Owner | Sale | 40,416 | $6.52 | $263,512.32 | View Details |
| Apr 7, 2026 | ORBIMED ADVISORS LLC 10% Owner | Sale | 2,400 | $6.38 | $15,312.00 | View Details |
| Apr 7, 2026 | ORBIMED ADVISORS LLC 10% Owner | Sale | 29,319 | $6.53 | $191,453.07 | View Details |
2 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$2.91
Actual-$2.94
Miss
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$3.23
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$TRAW โ Traws Pharma, Inc.via ORBIMED ADVISORS LLC$CDTX โ Cidara Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$WVE โ Wave Life Sciences Ltd.via RA CAPITAL MANAGEMENT, L.P.$PRLD โ Prelude Therapeutics Incvia ORBIMED ADVISORS LLC$STTK โ Shattuck Labs, Inc.via ORBIMED ADVISORS LLC$EWTX โ Edgewise Therapeutics, Inc.via ORBIMED ADVISORS LLC$CLYM โ Climb Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$MBX โ MBX Biosciences, Inc.via ORBIMED ADVISORS LLC$SGP โ SpyGlass Pharma, Inc. Common Stockvia RA CAPITAL MANAGEMENT, L.P.$ETNB โ 89bio, Inc.via RA CAPITAL MANAGEMENT, L.P.